Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
RNA-seq (gene expression) · mouse · 2 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 2 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1Cancer cell · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE268610_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1117900 and SRA study SRP510665. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 2 more — browse all 2 samples with per-sample file links →
- GSE296837 IFN-γ-induced PD-L1+ and MHC II+ macrophages and Tim-3+ tumor-reactive CD8+ T cells predict a positive response to anti-PD-1 therapy in tumor-bearing mice 28 samples shares anti-pd-1, pd-l1
- GSE271663 Tumor-Suppressing Multi-Enterobacteria enhance the anti-PD-1/PD-L1 efficacy in microsatellite stable colorectal cancer 36 samples shares anti-pd-1, pd-l1
- GSE251922 DAV132 colon-targeted adsorbent prevents antibiotic-related dysbiosis in human volunteers and mitigates anti-PD-1 resistance in murine models 39 samples shares anti-pd-1, resistance
- GSE328461 Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models 37 samples shares pd-l1, resistance
- GSE315244 Immune Checkpoint B7x Promotes Immune Evasion and Resistance to PD-1/PD-L1 Blockade in Bladder Cancer 15 samples shares pd-l1, resistance
- GSE241539 Osteopontin links acquired resistance to hypoxia-inducing antiangiogenics with refractoriness to anti-PD-L1 agents in breast cancer 13 samples shares pd-l1, resistance
- GSE186037 Gene expression changes in mouse kidney cancer cells (RENCA) after anti-PD-L1 resistance 12 samples shares pd-l1, resistance
- GSE265991 Pien Tze Huang enhances the killing effect of autologous T cells in colorectal cancer by inhibiting PD-L1, stem cell markers, and STAT3. 12 samples shares pd-l1, inhibiting
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.